Tesamorelin

Also known as: Egrifta, TH9507

The GH-releasing peptide with the strongest evidence — because it was developed and approved as a medicine.

Growth-hormone secretagoguesEvidence for fitness claims:Well-supported· human data

Regulatory status: FDA-approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.

What it is

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary to release growth hormone. It is a genuine peptide medicine — developed, trialled and approved — which makes it the useful reference point for this whole section.

Composition

It is a modified version of the 44-amino-acid human GHRH, stabilised so it survives longer in the body than the natural hormone. It works with your own hormonal machinery — prompting the pituitary to release growth hormone in a more natural, pulsatile way — rather than being growth hormone itself.

Proposed mechanism

By activating GHRH receptors on the pituitary, tesamorelin increases the body’s own growth-hormone (and downstream IGF-1) output. In its approved use, the relevant effect is a reduction in visceral (deep abdominal) fat.

Claimed benefits

Within fitness circles it is claimed to reduce stubborn abdominal fat, improve body composition and offer anti-ageing effects. The approved, evidenced claim is narrower than the marketing.

What the evidence shows

Well-supported· human data — for its approved use. Large randomised, placebo-controlled trials (Falutz and colleagues, New England Journal of Medicine, 2007, and later analyses) showed tesamorelin selectively reduced visceral fat by roughly 15–18% over 6–12 months in people with HIV-associated lipodystrophy, without changing subcutaneous fat or overall BMI. That is a real, imaging-confirmed effect — in that specific population.

What the evidence does not establish is muscle-building, fat loss in healthy athletes, or anti-ageing benefit — those uses are off-label and unstudied. The strong evidence is for one condition, not for general physique enhancement.

Legal & regulatory status

Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy — prescription-only, for that indication. It is not approved for fitness or anti-ageing use anywhere, and grey-market “research” tesamorelin is an unlicensed product. As a growth-hormone-releasing factor it is prohibited in sport under the WADA code, in and out of competition.

Known risks & unknowns

In trials, injection-site reactions, joint aches, fluid retention and effects on glucose tolerance were noted; growth-hormone-axis drugs are generally avoided in active cancer. Its safety was characterised in a specific patient group over defined periods — long-term use in healthy people for physique goals is outside what has been studied, and grey-market products add the usual purity and dosing unknowns.

Sources

Frequently asked questions

Is tesamorelin approved by regulators?
Yes — it is FDA-approved (as Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. That is its only approved use; it is not approved for general fitness, physique or anti-ageing purposes.
Does tesamorelin build muscle?
That is not what it was approved for and not what the trials measured. Its evidence base is about reducing visceral fat in a specific patient group. Using it for muscle gain is off-label and unstudied for that purpose.
Why is tesamorelin the 'good evidence' example here?
Because it went through the full drug-development process — large randomised placebo-controlled trials with imaging endpoints — which almost none of the other compounds in this section have. It shows what real evidence looks like, and how far most 'research peptides' fall short of it.
Is tesamorelin allowed in sport?
No. As a growth-hormone-releasing factor it falls under the WADA prohibited list (peptide hormones and releasing factors) and is banned in and out of competition.

Related compounds

  • MK-677 (Ibutamoren) — Preliminary

    An evidence-tiered explainer on MK-677 (ibutamoren): an oral ghrelin-receptor agonist — technically not a peptide — that raises GH and IGF-1, with real but modest human trial data and no approval.

  • HGH Fragment 176-191 — Marketing claim

    An evidence-tiered explainer on HGH Fragment 176-191 / AOD-9604: a growth-hormone fragment marketed for fat loss whose largest human trial failed, leading its developer to abandon it.

  • GLP-1 receptor agonists — Well-supported

    How GLP-1 receptor agonists (semaglutide, tirzepatide) differ from the unregulated 'research peptides': real large-scale trials, regulatory approval, and prescription-only status.

Written and reviewed by Mathew Beale — MSc Biotechnology, University of Reading.

Last reviewed: